Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organization (CDMO), held a grand opening event at their recently acquired solid oral dosage drug product manufacturing facility in Sellersville, PA.

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions, explained that this acquisition broadens the offering of Piramal Pharma Solutions by adding solid oral dosage form capabilities (tablets and capsules) in North America. He said, “This is a big day for us. We are rapidly growing and we take pride in the fact that we let our customer’s guide how and where we grow. The Sellersville facility is a great example of this. It was acquired because it addresses a market need for solid oral dosage form development and manufacturing in the United States. It also gives us new capabilities in liquids, creams, and ointments. As a leading CDMO offering end-to-end solutions across the drug life cycle, it’s vital that we provide our customers with a complete suite of services in all major geographies.”

John Fowler, Chief Operating Officer, Piramal Pharma Solutions, added, “Bringing the Sellersville site into the family significantly helps us accomplish our goal of getting medicines to patients. This is the thirteenth facility in our global network and our first solid dose facility in North America, giving us critical mass that matches local market need.” Stuart Needleman, Chief Commercial Officer, Piramal Pharma Solutions, added, “As a patient-centric organization, our mission is to help our customers reduce the burden of disease on patients. It’s the reason why we get up in the morning. And the Sellersville site most definitely enhances our ability to do that.”